Drugs / AK0610
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06996704 | Feb 2024 → Jun 2025 overdue | — | Shanghai Ark Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK0610 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06996704 ↗ |
| Route | Intramuscular | “Route of Administration: Intramuscular injection or intravenous injection.” NCT06996704 ↗ |
| Route | Intravenous | “Route of Administration: Intramuscular injection or intravenous injection.” NCT06996704 ↗ |